{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T03:16:32Z","timestamp":1792293392574,"version":"4.4.0"},"reference-count":22,"publisher":"American Diabetes Association","issue":"8","license":[{"start":{"date-parts":[[2017,2,1]],"date-time":"2017-02-01T00:00:00Z","timestamp":1485907200000},"content-version":"vor","delay-in-days":254,"URL":"http:\/\/www.diabetesjournals.org\/site\/license"}],"funder":[{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["diabetesjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2016,8,1]]},"abstract":"<jats:sec>\n                  <jats:title>OBJECTIVE<\/jats:title>\n                  <jats:p>To provide evidence-based options on how to intensify basal insulin, we explored head-to-head prandial interventions in overweight patients with type 2 diabetes inadequately controlled on basal insulin glargine with or without 1\u20133 oral antidiabetic agents (OADs).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>RESEARCH DESIGN AND METHODS<\/jats:title>\n                  <jats:p>Patients were randomized to lixisenatide once daily or insulin glulisine given once or thrice daily, added to glargine, with or without metformin, if HbA1c remained \u22657 to \u22649% (\u226553 to \u226475 mmol\/mol) after 12 weeks of glargine optimization with OADs other than metformin stopped at the start of optimization. Coprimary end points at 26 weeks were 1) noninferiority (95% CI upper bound &amp;lt;0.4% [&amp;lt;4.4 mmol\/mol]) in HbA1c reduction with lixisenatide versus glulisine once daily, and either 2a) noninferiority in HbA1c reduction for lixisenatide versus glulisine thrice daily or 2b) superiority in body weight change for lixisenatide versus glulisine thrice daily. Fasting and postprandial plasma glucose, composite efficacy\/safety end points, and adverse events were also assessed.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>RESULTS<\/jats:title>\n                  <jats:p>Baseline characteristics were similar between arms (n = 298, diabetes and basal insulin duration of 12.2 and 3.2 years, respectively; BMI 32.2 kg\/m2). HbA1c improved from 8.5% to 7.9% (69 to 63 mmol\/mol) with glargine optimization and further to 7.2%, 7.2%, and 7.0% (55, 55, and 53 mmol\/mol) with lixisenatide and glulisine once daily and thrice daily, respectively; all coprimary end points were met. Symptomatic hypoglycemia and body weight were lower in lixisenatide versus glulisine patients. More gastrointestinal events occurred with lixisenatide.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>CONCLUSIONS<\/jats:title>\n                  <jats:p>Short-acting glucagon-like peptide-1 receptor agonists as add-on to basal insulin may become a preferred treatment intensification option, attaining meaningful glycemic targets with fewer hypoglycemic events without weight gain versus basal-plus or basal-bolus in uncontrolled basal insulin-treated type 2 diabetes.<\/jats:p>\n               <\/jats:sec>","DOI":"10.2337\/dc16-0014","type":"journal-article","created":{"date-parts":[[2016,5,25]],"date-time":"2016-05-25T00:29:09Z","timestamp":1464136149000},"page":"1318-1328","update-policy":"https:\/\/doi.org\/10.2337\/ada-journal-policies","source":"Crossref","is-referenced-by-count":123,"title":["Prandial Options to Advance Basal Insulin Glargine Therapy: Testing Lixisenatide Plus Basal Insulin Versus Insulin Glulisine Either as Basal-Plus or Basal-Bolus in Type 2 Diabetes: The GetGoal Duo-2 Trial"],"prefix":"10.2337","volume":"39","author":[{"given":"Julio","family":"Rosenstock","sequence":"first","affiliation":[{"name":"Dallas Diabetes and Endocrine Center at Medical City, Dallas, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Guerci","sequence":"additional","affiliation":[{"name":"University of Lorraine and the Department of Diabetology, Metabolic Diseases and Nutrition, Brabois Adult Hospital, Vand\u0153uvre-l\u00e8s-Nancy, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markolf","family":"Hanefeld","sequence":"additional","affiliation":[{"name":"GWT-TUD, Study Centre Prof. Hanefeld, Dresden Technical University, Dresden, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandro","family":"Gentile","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Medicine, Second University of Naples, Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronnie","family":"Aronson","sequence":"additional","affiliation":[{"name":"LMC Diabetes & Endocrinology, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco J.","family":"Tinahones","sequence":"additional","affiliation":[{"name":"Centre in Physiopathology of Obesity and Nutrition (CIBEROBN), Carlos III Institute of Health and Hospital Virgen de la Victoria, Malaga, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Roy-Duval","sequence":"additional","affiliation":[{"name":"Sanofi, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"Souhami","sequence":"additional","affiliation":[{"name":"Sanofi, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marek","family":"Wardecki","sequence":"additional","affiliation":[{"name":"Sanofi, Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenny","family":"Ye","sequence":"additional","affiliation":[{"name":"Sanofi, Bridgewater, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riccardo","family":"Perfetti","sequence":"additional","affiliation":[{"name":"Sanofi, Bridgewater, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Heller","sequence":"additional","affiliation":[{"name":"Academic Unit of Diabetes, Endocrinology and Metabolism, University of Sheffield, Sheffield, U.K."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1167","published-online":{"date-parts":[[2016,5,23]]},"reference":[{"key":"2022031301030199600_B1","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.2337\/dc12-0413","article-title":"Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)","volume":"35","author":"Inzucchi","year":"2012","journal-title":"Diabetes Care"},{"key":"2022031301030199600_B2","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1111\/dom.12225","article-title":"Randomized, 1-year comparison of three ways to initiate and advance insulin for type 2 diabetes: twice-daily premixed insulin versus basal insulin with either basal-plus one prandial insulin or basal-bolus up to three prandial injections","volume":"16","author":"Riddle","year":"2014","journal-title":"Diabetes Obes Metab"},{"key":"2022031301030199600_B3","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/S0140-6736(98)07019-6","article-title":"Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)","volume":"352","author":"UK Prospective Diabetes Study (UKPDS) Group","year":"1998","journal-title":"Lancet"},{"key":"2022031301030199600_B4","doi-asserted-by":"crossref","first-page":"140","DOI":"10.2337\/dc14-2441","article-title":"Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes","volume":"38","author":"Inzucchi","year":"2015","journal-title":"Diabetes Care"},{"key":"2022031301030199600_B5","doi-asserted-by":"crossref","first-page":"240","DOI":"10.2337\/dc09-1348","article-title":"Correlates of insulin injection omission","volume":"33","author":"Peyrot","year":"2010","journal-title":"Diabetes Care"},{"key":"2022031301030199600_B6","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1111\/dom.12290","article-title":"Pronounced reduction of postprandial glucagon by lixisenatide: a meta-analysis of randomized clinical trials","volume":"16","author":"Ahr\u00e9n","year":"2014","journal-title":"Diabetes Obes Metab"},{"key":"2022031301030199600_B7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.regpep.2013.04.001","article-title":"Effects of lixisenatide once daily on gastric emptying in type 2 diabetes--relationship to postprandial glycemia","volume":"185","author":"Lorenz","year":"2013","journal-title":"Regul Pept"},{"key":"2022031301030199600_B8","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1038\/nrendo.2012.140","article-title":"GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus","volume":"8","author":"Meier","year":"2012","journal-title":"Nat Rev Endocrinol"},{"key":"2022031301030199600_B9","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.2337\/dc14-1984","article-title":"Contrasting effects of lixisenatide and liraglutide on post-prandial glycemic control, gastric emptying, and safety parameters in patients with type 2 diabetes on optimized insulin glargine with or without metformin: a randomized, open-label trial","volume":"38","author":"Meier","year":"2015","journal-title":"Diabetes Care"},{"key":"2022031301030199600_B10","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.2337\/dc12-2454","article-title":"Adding once-daily lixisenatide for type 2 diabetes inadequately controlled by established basal insulin: a 24-week, randomized, placebo-controlled comparison (GetGoal-L)","volume":"36","author":"Riddle","year":"2013","journal-title":"Diabetes Care"},{"key":"2022031301030199600_B11","doi-asserted-by":"crossref","first-page":"3080","DOI":"10.2337\/diacare.26.11.3080","article-title":"The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients","volume":"26","author":"Riddle","year":"2003","journal-title":"Diabetes Care"},{"key":"2022031301030199600_B12","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S1262-3636(07)70241-0","article-title":"Addition of rapid-acting insulin to basal insulin therapy in type 2 diabetes: indications and modalities","volume":"32","author":"Monnier","year":"2006","journal-title":"Diabetes Metab"},{"key":"2022031301030199600_B13","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1001\/archinternmed.2009.193","article-title":"Modern-day clinical course of type 1 diabetes mellitus after 30 years\u2019 duration: the diabetes control and complications trial\/epidemiology of diabetes interventions and complications and Pittsburgh epidemiology of diabetes complications experience (1983-2005)","volume":"169","author":"Nathan","year":"2009","journal-title":"Arch Intern Med"},{"key":"2022031301030199600_B14","doi-asserted-by":"crossref","first-page":"2948","DOI":"10.2337\/diacare.28.12.2948","article-title":"Hypoglycemia in type 2 diabetes: pathophysiology, frequency, and effects of different treatment modalities","volume":"28","author":"Zammitt","year":"2005","journal-title":"Diabetes Care"},{"key":"2022031301030199600_B15","doi-asserted-by":"crossref","first-page":"604","DOI":"10.2337\/dc10-1900","article-title":"Exenatide twice daily versus premixed insulin aspart 70\/30 in metformin-treated patients with type 2 diabetes: a randomized 26-week study on glycemic control and hypoglycemia","volume":"34","author":"Gallwitz","year":"2011","journal-title":"Diabetes Care"},{"key":"2022031301030199600_B16","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1111\/j.1463-1326.2010.01356.x","article-title":"Liraglutide, a once-daily human glucagon-like peptide 1 analogue, provides sustained improvements in glycaemic control and weight for 2 years as monotherapy compared with glimepiride in patients with type 2 diabetes","volume":"13","author":"Garber","year":"2011","journal-title":"Diabetes Obes Metab"},{"key":"2022031301030199600_B17","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.2337\/dc09-0366","article-title":"Potential of albiglutide, a long-acting GLP-1 receptor agonist, in type 2 diabetes: a randomized controlled trial exploring weekly, biweekly, and monthly dosing","volume":"32","author":"Rosenstock","year":"2009","journal-title":"Diabetes Care"},{"key":"2022031301030199600_B18","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.jdiacomp.2013.10.003","article-title":"Once-daily prandial lixisenatide versus once-daily rapid-acting insulin in patients with type 2 diabetes mellitus insufficiently controlled with basal insulin: analysis of data from five randomized, controlled trials","volume":"28","author":"Raccah","year":"2014","journal-title":"J Diabetes Complications"},{"key":"2022031301030199600_B19","doi-asserted-by":"crossref","first-page":"2763","DOI":"10.2337\/dc14-0876","article-title":"Glucagon-like peptide 1 receptor agonist or bolus insulin with optimized basal insulin in type 2 diabetes","volume":"37","author":"Diamant","year":"2014","journal-title":"Diabetes Care"},{"key":"2022031301030199600_B20","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.2337\/dc14-0001","article-title":"Advancing basal insulin replacement in type 2 diabetes inadequately controlled with insulin glargine plus oral agents: a comparison of adding albiglutide, a weekly GLP-1 receptor agonist, versus thrice-daily prandial insulin lispro","volume":"37","author":"Rosenstock","year":"2014","journal-title":"Diabetes Care"},{"key":"2022031301030199600_B21","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1111\/dom.12262","article-title":"A comparison of adding liraglutide versus a single daily dose of insulin aspart to insulin degludec in subjects with type 2 diabetes (BEGIN: VICTOZA ADD-ON)","volume":"16","author":"Mathieu","year":"2014","journal-title":"Diabetes Obes Metab"},{"key":"2022031301030199600_B22","doi-asserted-by":"crossref","first-page":"E155","DOI":"10.1152\/ajpendo.2001.281.1.E155","article-title":"Exendin-4 reduces fasting and postprandial glucose and decreases energy intake in healthy volunteers","volume":"281","author":"Edwards","year":"2001","journal-title":"Am J Physiol Endocrinol Metab"}],"container-title":["Diabetes Care"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/care.diabetesjournals.org\/syndication\/doi\/10.2337\/dc16-0014","content-type":"unspecified","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/39\/8\/1318\/626673\/dc160014.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/39\/8\/1318\/626673\/dc160014.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,13]],"date-time":"2022-03-13T04:38:37Z","timestamp":1647146317000},"score":1,"resource":{"primary":{"URL":"https:\/\/diabetesjournals.org\/care\/article\/39\/8\/1318\/37123\/Prandial-Options-to-Advance-Basal-Insulin-Glargine"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5,23]]},"references-count":22,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2016,5,23]]},"published-print":{"date-parts":[[2016,8,1]]}},"URL":"https:\/\/doi.org\/10.2337\/dc16-0014","relation":{},"ISSN":["0149-5992","1935-5548"],"issn-type":[{"value":"0149-5992","type":"print"},{"value":"1935-5548","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,5,23]]}}}